Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
about
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicityPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyA role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivoThe use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.International recommendations on the diagnosis and treatment of patients with acquired hemophilia AClinical advances in hemophilia management.Immune tolerance induction for patients with severe hemophilia A: a critical literature review.Management of bleeding disorders: basic science.A review of immune tolerance induction with Haemate P in haemophilia A.Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.New predictive approaches for ITI treatment.Immune tolerance induction in patients with severe hemophilia A with inhibitorsInhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor.Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.Partnering to change the world for people with haemophilia: 7th Haemophilia Global Summit, Madrid, Spain 22-24 September 2016.Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.
P2860
Q26866323-4F0556B8-AD34-4A1F-B006-B9426C35D052Q34416394-1253A988-496B-4BF8-8F65-85FD154E5ECDQ35176160-6D538B6D-1573-4FBD-91CF-DFE6E11FF094Q36661822-9E27336F-C634-499E-A26F-26FD0E4F23CFQ36707550-75BB0CF2-5D09-444F-B5A4-35836F8EE6B3Q36897565-4256B28F-F7CD-41EB-BC4C-ACE342A940A1Q37032857-5EE4A1EA-EEA7-42AC-863E-A13675CB75C7Q37124978-4A5CDCF8-14C7-489D-A404-8BF32C1C0E0CQ37146064-C74AE628-39C5-4932-B04E-7C499F41F39EQ37900933-1506F503-0E9B-4EF4-9F04-41D3D22F6296Q37912059-D0D6171B-3202-4475-9C55-3835D5D4B195Q38005178-DED6BF95-5298-4815-BD39-AA4D06DBF3DEQ38156000-23F40C42-D285-4757-AD64-1E80212FB2ADQ38224295-678DFD6C-865D-4CCD-9EEC-4D345927C659Q38224297-F2142D2E-0115-478A-A542-423130A5EDECQ38697680-D3E4541F-B552-42C9-B981-9F57B3BDAD19Q38722283-D503F53A-D8F4-440F-91E2-1044F6E47353Q41809588-CCBB1AEC-07C7-429F-BD59-9BD889D710F7Q42408107-8CE534A9-B6C7-4FF1-8623-A59F93BC8D60Q45864893-7B6D5136-B1A0-45A5-8341-FD8F4CFFBA60Q45869290-A154DE0E-3510-4D9C-B4DE-34ABC5E4A44AQ45871996-78098165-1D43-484A-826C-EB3A33DBECB4Q45872095-F03069AF-28C1-4A72-8105-063BAEE28CF2Q45873491-7DD610D4-45A0-4EA9-A332-AFCB8A6F16A1
P2860
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Impact of inhibitor epitope pr ...... or VIII concentrates in vitro.
@en
Impact of inhibitor epitope pr ...... or VIII concentrates in vitro.
@nl
type
label
Impact of inhibitor epitope pr ...... or VIII concentrates in vitro.
@en
Impact of inhibitor epitope pr ...... or VIII concentrates in vitro.
@nl
prefLabel
Impact of inhibitor epitope pr ...... or VIII concentrates in vitro.
@en
Impact of inhibitor epitope pr ...... or VIII concentrates in vitro.
@nl
P2093
P2860
P1433
P1476
Impact of inhibitor epitope pr ...... tor VIII concentrates in vitro
@en
P2093
D DiMichele
E Berntorp
G Tjönnfjord
J Astermark
P2860
P304
P356
10.1046/J.1365-2516.2003.00802.X
P50
P577
2003-09-01T00:00:00Z